INSIGHTS Trademark
Trademark Overview
On Friday, February 9, 2024, a trademark application was filed for INSIGHTS with the United States Patent and Trademark Office. The USPTO has given the INSIGHTS trademark a serial number of 98400249. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, September 4, 2024. This trademark is owned by FRESENIUS MEDICAL CARE HOLDINGS, INC.. The INSIGHTS trademark is filed in the Medical Instrument Products and Computer & Software Services & Scientific Services categories with the following description:
Sensors connected to dialysis machines as well as sensors integrated into bloodlines for medical use to collect patient data; for assisting healthcare professionals with managing hemoglobin levels or managing anemia in End Stage Renal Disease and Chronic Kidney Disease patients by recommending optimized Erythropoietin Stimulating Agents drug dosages, including no dosage and iron dosages
Cloud computing featuring software using patient data to assist healthcare professionals with managing hemoglobin levels or managing anemia in End Stage Renal Disease and Chronic Kidney Disease patients by recommending optimized Erythropoietin Stimulating Agents drug dosages, including no dosage and iron dosages
General Information
Serial Number | 98400249 |
Word Mark | INSIGHTS |
Filing Date | Friday, February 9, 2024 |
Status | 641 - NON-FINAL ACTION - MAILED |
Status Date | Wednesday, September 4, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
Description of Mark | The mark consists of the stylized word "inSights" with "Sights" in a bold font. |
Pseudo Mark | IN SIGHTS |
Indication of Colors claimed | Color is not claimed as a feature of the mark. |
Goods and Services | Sensors connected to dialysis machines as well as sensors integrated into bloodlines for medical use to collect patient data; for assisting healthcare professionals with managing hemoglobin levels or managing anemia in End Stage Renal Disease and Chronic Kidney Disease patients by recommending optimized Erythropoietin Stimulating Agents drug dosages, including no dosage and iron dosages |
Goods and Services | Cloud computing featuring software using patient data to assist healthcare professionals with managing hemoglobin levels or managing anemia in End Stage Renal Disease and Chronic Kidney Disease patients by recommending optimized Erythropoietin Stimulating Agents drug dosages, including no dosage and iron dosages |
Classification Information
International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
US Class Codes | 026, 039, 044 |
Class Status Code | 6 - Active |
Class Status Date | Friday, February 9, 2024 |
Primary Code | 010 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, February 9, 2024 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | FRESENIUS MEDICAL CARE HOLDINGS, INC. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | WALTHAM, MA 02451 |
Trademark Events
Event Date | Event Description |
Friday, February 9, 2024 | NEW APPLICATION ENTERED |
Wednesday, June 12, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Wednesday, September 4, 2024 | NON-FINAL ACTION E-MAILED |
Wednesday, September 4, 2024 | NON-FINAL ACTION WRITTEN |
Wednesday, September 4, 2024 | ASSIGNED TO EXAMINER |
Wednesday, September 4, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, November 26, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
Tuesday, November 26, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |